Bright Minds Biosciences Inc (DRUG) — Strategic Asset Allocation Index
Bright Minds Biosciences Inc (DRUG) has a Strategic Asset Allocation Index of 1.1% as of December 2022. Strategic assets (PP&E of $120.75K plus long-term investments of $-) total $120.75K, measured against net assets of $10.97 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see DRUG company net worth.
SAAI
Strategic Assets
PP&E
Net Assets
Bright Minds Biosciences Inc Strategic Asset Allocation Index (2022–2022)
This chart shows how Bright Minds Biosciences Inc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of December 2022, the index stands at 1.1%, representing strategic assets of $120.75K against net assets of $10.97 Million USD. See Bright Minds Biosciences Inc (DRUG) net asset quality to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Bright Minds Biosciences Inc (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Bright Minds Biosciences Inc from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore Bright Minds Biosciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.3% | $138.86K | $138.86K | $- | $10.54 Million | — |